2012 Q3 Form 10-Q Financial Statement
#000110465912076010 Filed on November 08, 2012
Income Statement
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| Revenue | $5.036M | $182.8K |
| YoY Change | 2655.18% | 256.09% |
| Cost Of Revenue | $2.322M | |
| YoY Change | ||
| Gross Profit | $2.714M | |
| YoY Change | ||
| Gross Profit Margin | 53.9% | |
| Selling, General & Admin | $1.257M | $1.680M |
| YoY Change | -25.19% | 9.8% |
| % of Gross Profit | 46.3% | |
| Research & Development | $148.7K | $11.50M |
| YoY Change | -98.71% | 18.36% |
| % of Gross Profit | 5.48% | |
| Depreciation & Amortization | $144.0K | $35.67K |
| YoY Change | 303.59% | -13.0% |
| % of Gross Profit | 5.3% | |
| Operating Expenses | $1.405M | $11.50M |
| YoY Change | -87.78% | 18.36% |
| Operating Profit | -$207.4K | -$13.03M |
| YoY Change | -98.41% | 15.91% |
| Interest Expense | $81.23K | $172.0K |
| YoY Change | -52.78% | 0.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$91.21K | $0.00 |
| YoY Change | ||
| Pretax Income | -$379.8K | -$12.73M |
| YoY Change | -97.02% | 9.84% |
| Income Tax | $866.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$377.3K | -$12.73M |
| YoY Change | -97.04% | 9.84% |
| Net Earnings / Revenue | -7.49% | -6964.5% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.602M | -$4.390M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 22.92M shares | 17.41M shares |
| Diluted Shares Outstanding | 22.92M shares | 17.41M shares |
Balance Sheet
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $38.00M | $69.60M |
| YoY Change | -45.4% | 96.06% |
| Cash & Equivalents | $148.3K | $69.60M |
| Short-Term Investments | ||
| Other Short-Term Assets | $500.0K | $900.0K |
| YoY Change | -44.44% | -25.0% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $38.58M | $70.50M |
| YoY Change | -45.27% | 92.1% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $1.185M | $900.0K |
| YoY Change | 31.64% | 50.0% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $3.400M | $3.400M |
| YoY Change | 0.0% | 3.03% |
| Other Assets | $0.00 | $100.0K |
| YoY Change | -100.0% | 0.0% |
| Total Long-Term Assets | $4.629M | $4.400M |
| YoY Change | 5.2% | 7.32% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $38.58M | $70.50M |
| Total Long-Term Assets | $4.629M | $4.400M |
| Total Assets | $43.21M | $74.90M |
| YoY Change | -42.31% | 83.58% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.005M | $6.000M |
| YoY Change | -66.59% | 33.33% |
| Accrued Expenses | $1.300M | $4.200M |
| YoY Change | -69.05% | 61.54% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $7.600M | $1.200M |
| YoY Change | 533.33% | |
| Total Short-Term Liabilities | $10.92M | $11.50M |
| YoY Change | -5.03% | 61.97% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $19.20M |
| YoY Change | -100.0% | 4.35% |
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $19.20M |
| YoY Change | -100.0% | 4.35% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $10.92M | $11.50M |
| Total Long-Term Liabilities | $0.00 | $19.20M |
| Total Liabilities | $10.92M | $30.70M |
| YoY Change | -64.42% | 20.39% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$241.0M | -$210.6M |
| YoY Change | 14.43% | |
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $32.30M | $44.10M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $43.21M | $74.90M |
| YoY Change | -42.31% | 83.58% |
Cashflow Statement
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$377.3K | -$12.73M |
| YoY Change | -97.04% | 9.84% |
| Depreciation, Depletion And Amortization | $144.0K | $35.67K |
| YoY Change | 303.59% | -13.0% |
| Cash From Operating Activities | -$7.380M | -$12.58M |
| YoY Change | -41.34% | 15.94% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$470.0K | -$110.0K |
| YoY Change | 327.27% | 1000.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| Cash From Investing Activities | -$470.0K | -$110.0K |
| YoY Change | 327.27% | 1000.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 3.480M | 45.16M |
| YoY Change | -92.29% | |
| NET CHANGE | ||
| Cash From Operating Activities | -7.380M | -12.58M |
| Cash From Investing Activities | -470.0K | -110.0K |
| Cash From Financing Activities | 3.480M | 45.16M |
| Net Change In Cash | -4.370M | 32.47M |
| YoY Change | -113.46% | -398.99% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$7.380M | -$12.58M |
| Capital Expenditures | -$470.0K | -$110.0K |
| Free Cash Flow | -$6.910M | -$12.47M |
| YoY Change | -44.59% | 15.04% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
801147 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
58026381 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
861364 | USD |
| CY2011Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
3405807 | USD |
| CY2011Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
86203 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
62379755 | USD |
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3150677 | USD |
| CY2011Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2479697 | USD |
| CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7227703 | USD |
| CY2011Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
17336760 | USD |
| CY2011Q4 | us-gaap |
Liabilities
Liabilities
|
24564463 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-217239148 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
57225234 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37815292 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
62379755 | USD |
| CY2012Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-240969556 | USD |
| CY2011Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
255054440 | USD |
| CY2011Q3 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
82784 | USD |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
182784 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
110383 | USD |
| us-gaap |
Revenues
Revenues
|
333163 | USD | |
| CY2011Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1675268 | USD |
| CY2011Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
35670 | USD |
| CY2011Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
13210991 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
37480873 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5257853 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
118132 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-367274 | USD | |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
42856858 | USD | |
| CY2011Q3 | us-gaap |
Interest Expense
InterestExpense
|
172000 | USD |
| CY2011Q3 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
2000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
516000 | USD | |
| us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
15000 | USD | |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12733691 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-44959599 | USD | |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.73 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.86 | ||
| CY2011Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17406536 | shares |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
17406536 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15744738 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15744738 | shares | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
180759 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1539903 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2993059 | USD | |
| CY2012Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
43211746 | USD |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
220787 | USD | |
| us-gaap |
Revenues
Revenues
|
320787 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-36944908 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
645603 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-536697 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
32442 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
23876370 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
69035459 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
344000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
184094 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
24063 | USD | |
| CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38049095 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38155251 | USD |
| CY2011Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
69600199 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3479208 | USD | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">                                    </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">DESCRIPTION OF BUSINESS</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">BioSante Pharmaceuticals, Inc.’s (the Company) corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company’s products, either approved or in clinical development, include: (1) LibiGel, once daily transdermal testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2) a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA, Inc. (Teva); (3) GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and which are currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers; (4) The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (5) Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals Inc. (Meda), the Company’s licensee.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">                                    </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">BASIS OF PRESENTATION</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of September 30, 2012 and December 31, 2011, the results of operations for the three and nine months ended September 30, 2012 and 2011, and the cash flows for the nine months ended September 30, 2012 and 2011, in conformity with accounting principles generally accepted in the United States of America (GAAP).  Operating results for the three and nine month periods ended September 30, 2012 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2012.  The Company does not have items of other comprehensive income for either of the three or nine month periods ended September 30, 2012 or 2011; and therefore, has not presented comprehensive income.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">These unaudited interim condensed financial statements should be read in conjunction with the financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On June 1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class C special stock.  These unaudited interim condensed financial statements give retroactive effect to the reverse stock split.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-4037797 | USD | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
20841417 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
20841417 | shares | |
| CY2012Q3 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-843412 | USD |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.14 | ||
| CY2012Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1184764 | USD |
| dei |
Entity Registrant Name
EntityRegistrantName
|
BIOSANTE PHARMACEUTICALS INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001023024 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-09-30 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| CY2012Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10922066 | USD |
| CY2011Q3 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
463000 | USD |
| us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-1929000 | USD | |
| CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
5445349 | USD |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
19869517 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
31444948 | USD | |
| bpax |
Number Of Vaccines Granted With Fda Orphan Drug Designation
NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation
|
4 | vaccine | |
| bpax |
Proceeds From Issuance Of Common Stock By Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering
|
45102584 | USD | |
| CY2012Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
981272 | shares |
| CY2011Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1516 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
6472 | USD | |
| us-gaap |
Stock Issued1
StockIssued1
|
13881052 | USD | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
59016 | USD | |
| CY2012Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22921176 | shares |
| CY2012Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22921176 | shares |
| CY2012Q3 | us-gaap |
Assets
Assets
|
43211746 | USD |
| CY2012Q3 | us-gaap |
Senior Notes Current
SeniorNotesCurrent
|
7593216 | USD |
| CY2012Q3 | us-gaap |
Liabilities
Liabilities
|
10922066 | USD |
| CY2012Q3 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
273259236 | USD |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
7955 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-19176139 | USD | |
| CY2012Q2 | bpax |
Stockholders Equity Reverse Stock Split Conversion Ratio
StockholdersEquityReverseStockSplitConversionRatio
|
0.1667 | pure |
| bpax |
Unpaid Costs Associated With Under Written Public Offering
UnpaidCostsAssociatedWithUnderWrittenPublicOffering
|
141447 | USD | |
| bpax |
Number Of Phase I And Phase Ii Clinical Trials
NumberOfPhaseIAndPhaseIIClinicalTrials
|
17 | item | |
| CY2011Q3 | us-gaap |
Licenses Revenue
LicensesRevenue
|
100000 | USD |
| us-gaap |
Licenses Revenue
LicensesRevenue
|
100000 | USD | |
| CY2012Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
534037 | USD |
| CY2012Q3 | us-gaap |
Assets Current
AssetsCurrent
|
38583132 | USD |
| CY2012Q3 | us-gaap |
Long Term Investments
LongTermInvestments
|
3413762 | USD |
| CY2012Q3 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
30088 | USD |
| CY2012Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2004814 | USD |
| CY2012Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
463942 | USD |
| CY2012Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
860094 | USD |
| CY2012Q3 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
110383 | USD |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
333163 | USD | |
| CY2012Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
25749 | USD |
| CY2012Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1546864 | USD |
| CY2012Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3872736 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14454258 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5327711 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
87548 | USD | |
| CY2012Q3 | us-gaap |
Interest Expense
InterestExpense
|
67105 | USD |
| CY2012Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1877 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
283348 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
5300 | USD | |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6121815 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-23730408 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-117794 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
852468 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-323225 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3807074 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-22118650 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
528742 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
211068 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3268798 | USD | |
| bpax |
Unpaid Costs Associated With Registered Direct Offering
UnpaidCostsAssociatedWithRegisteredDirectOffering
|
7933 | USD | |
| CY2012Q2 | bpax |
Payments To Fractional Share Payout
PaymentsToFractionalSharePayout
|
658 | USD |
